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Abstract
Coronary artery diseases (CAD) inflict a heavy economical and social burden on most populations and contribute
significantly to their morbidity and mortality rates. Low-density lipoprotein receptor (LDLR) associated familial
hypercholesterolemia (FH) is the most frequent Mendelian disorder and is a major risk factor for the development
of CAD. To date there is no cure for FH. The primary goal of clinical management is to control
hypercholesterolaemia in order to decrease the risk of atherosclerosis and to prevent CAD. Permanent phenotypic
correction with single administration of a gene therapeutic vector is a goal still needing to be achieved. The first ex
vivo clinical trial of gene therapy in FH was conducted nearly 18 years ago. Patients who had inherited LDLR gene
mutations were subjected to an aggressive surgical intervention involving partial hepatectomy to obtain the
patient’s own hepatocytes for ex vivo gene transfer with a replication deficient LDLR-retroviral vector. After
successful re-infusion of transduced cells through a catheter placed in the inferior mesenteric vein at the time of
liver resection, only low-level expression of the transferred LDLR gene was observed in the five patients enrolled in
the trial. In contrast, full reversal of hypercholesterolaemia was later demonstrated in in vivo preclinical studies
using LDLR-adenovirus mediated gene transfer. However, the high efficiency of cell division independent gene
transfer by adenovirus vectors is limited by their short-term persistence due to episomal maintenance and the
cytotoxicity of these highly immunogenic viruses. Novel long-term persisting vectors derived from adeno-
associated viruses and lentiviruses, are now available and investigations are underway to determine their safety and
efficiency in preparation for clinical application for a variety of diseases. Several novel non-viral based therapies
have also been developed recently to lower LDL-C serum levels in FH patients. This article reviews the progress
made in the 18 years since the first clinical trial for gene therapy of FH, with emphasis on the development,
design, performance and limitations of viral based gene transfer vectors used in studies to ameliorate the effects of
LDLR deficiency.
Introduction
Familial hypercholesterolaemia (FH) is primarily an
autosomal dominant disorder, characterised by a lifelong
elevation of serum cholesterol bound to low-density
lipoprotein (LDL). The primary causative defects in
approximately 85% of FH cases are mutations or dele-
tions in the plasma membrane Low Density Lipoprotein
Receptor (LDLR) encoding gene that is responsible for
clearing LDL-cholesterol (LDL-C) from the blood
stream by endocytosis and intracellular degradation [1].
Over 1000 different mutations in the LDLR gene on the
distal short arm of chromosome 19 (p13.1-p13.3) have
been described to date [2] and are recorded online at
http://www.ucl.ac.uk/ldlr/Current/ [3]. The second gene
responsible for fewer than 10% of FH cases encodes the
ligand for LDLR, namely Apolipoprotein B-100 (ApoB-
100), located on the short arm of chromosome 2 (p24)
[4]. Mutations in this gene reduce ligand affinity for the
receptors and cause reduced clearance of LDL particles
resulting in hypercholesterolemia [5], albeit normal
LDLR activity. A mutation in the codon for amino acid
3500 (CGG-to-CAG) was found to be a CG mutation
hotspot associated with defective LDLs and hypercholes-
terolemia [6]. The pathophysiological consequences
from LDLR or ApoB mutations are loss of protein func-
tion, which lead to monogenic FH. Defects in a third
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p32), have also been identified to cause monogenic FH
[7]. The convertase subtilisin/kexin type 9 (PCSK9)-gene
codes for an enzyme that has also been called ‘’neural
apoptosis regulated convertase 1’’, which has been pro-
posed to be involved in degrading the LDLR protein in
the lysosome and thus preventing it from recycling [8].
Gain of function mutations in the PCSK9 gene could
therefore cause increased degradation of LDLRs, reduced
numbers of receptors on the surface of the cell, and mono-
genic FH. An autosomal recessive form of FH caused by
loss of function mutations in the LDLRAP1 gene, which is
located on the short arm of chromosome 1p35-36.1, has
also been documented [9]. The clinical phenotype of the
autosomal recessive form is similar to that of the classic
homozygous FH caused by defects in the LDLR gene, but
it is generally less severe and more responsive to lipid-low-
ering therapy (reviewed in [10]). This article focuses on
LDLR-associated FH reviewing, the encountered obstacles,
the achieved progress and the future prospectives of
LDLR-gene therapy for this disease.
LDLR-associated FH
Owing to mutations in both alleles of the LDLR locus,
homozygous LDLR-associated FH patients present with
markedly elevated total serum cholesterol (>500 mg/dL,
13 mmol/L) and LDL-cholesterol levels (LDL-C, >450
mg/dL, 11.7 mmol/L). The deposition of insoluble cho-
lesterol causes xanthomata on the tendons of the hands
and feet, cutaneous planar and corneal arcus in early life
[11,12]. Atheroma of the aortic root and valve can lead
to myocardial infarction (MI) and sudden death before
the age of 30 years. Coronary artery disease (CAD) is
more common and more extensive in receptor negative
patients (mutations that completely eliminate receptor
functions) than in those with the receptor-defective type
(mutations that partially inactivate receptor function),
where there is residual receptor activity [12,13]. Hetero-
zygous patients typically have a lower serum cholesterol
level (250-450 mg/dL or 6.5-11.6 mmol/L) and LDL-C
(200-400 mg/dL or 5.2-10.4 mmol/L) with positive age
correlation. They develop the above clinical features at a
less accelerated rate, but if untreated most suffer a
severe MI and often sudden death or other cardiovascu-
lar events in the fourth or fifth decade of life. Due to
several hormonal factors, approximately 80% of hetero-
zygote men suffer from CAD, while only 20% to 30% of
women are moderately affected [14].
In most investigated populations, the heterozygote
form occurs in at least 1:500 and the homozygous form
in one in one million individuals [15], although in some
populations, for example the Afrikaner population in
South Africa, heterozygosity is found in less than 1:80
individuals [16,17]. This unusual high frequency is due
to founder effects and no heterozygote advantage has
been identified. Heterozygous FH is therefore the most
frequent clinically relevant Mendelian trait, being more
frequent than homozygous cystic fibrosis and sickle cell
anaemia.
Cholesterol levels alone are not sufficient to confirm a
diagnosis of FH because blood cholesterol levels vary
with age, gender and are population specific [18].
In addition, the range of blood cholesterol levels in FH
overlaps with that of people with non-genetic multifac-
torial hypercholesterolaemia, which reduces diagnostic
accuracy. Diagnostic criteria of FH, therefore, include
clinical symptoms and laboratory findings as well as the
family history of a dominant pattern of inheritance for
either premature coronary heart disease or hypercholes-
terolaemia, (reviewed in [18]).
The human LDLR is a multi-component single-chain
glycoprotein, which contains 839 amino acids in its
mature form, encoded by a gene of 45 kb in length [19].
The gene contains 18 exons of which 13 exons code for
protein sequences that show homology to other proteins
such as the C9 component [20], Epidermal Growth Fac-
tor (EGF) [21], blood coagulation factor IX, factor X
(FX) and protein C [22-24]. The mRNA transcript is
5.3 kb in length and encodes a protein of 860 amino
a c i d s .A b o u th a l fo ft h em R N Ac o n s t i t u t e sal o n g
3’ untranslated region that contains two and a half
copies of the Alu family of middle repetitive DNAs [25].
LDL-Receptors are expressed ubiquitously by almost all
somatic cells under control of sterol negative feedback,
mediated by three 16 bp imperfect repeats (sterol regu-
latory elements) and a TATA box like sequence in the
promoter [26]. Their function is to bind to apolipopro-
tein ligands, apoB-100 and apoE. Uptake of LDL is
mediated mainly through apoB-100 [27].
The mature human LDLR of 160 kDa is composed of
five domains, Figure 1. Exon 1 encodes a short 5’
untranslated region and 21 hydrophobic amino acids that
are not present in the mature protein. This sequence
functions as a signal peptide to direct the receptor
synthesising ribosomes to the Endoplasmic Reticulum
(ER) membrane [25]. Other functional domains of the
peptide correspond to the exons as indicated in Figure 1,
41 bp of exon 17 plus exon 16 encode the transmem-
brane domain and the reminder of exon 17 together with
exon 18 encode the cytoplasmic domain.
Analyses of LDLR-associated FH variants estimated
that there were 1066 LDLR gene mutations/rearrange-
ments, 65% (n = 689) of which were DNA substitutions,
24% (n = 260) small DNA rearrangements (<100 bp), and
11% (n = 117) large DNA rearrangements (>100 bp) [2].
The DNA substitutions and small rearrangements occur
along the length of the gene, with 839 in the exons (93
nonsense variants, 499 missense variants and 247 small
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promoter region. The highest proportion of exon variants
occurs in the ligand binding domain (exons 2-6) and the
EGF precursor domain (exons 7-14) [2].
Clinical management of FH
T od a t et h e r ei sn oc u r ef o rF H .T h ep r i m a r yg o a lo f
clinical management in heterozygotes is to control
hypercholesterolaemia by lifestyle modification and/or
Figure 1 Schematic representation of the human LDLR gene, mRNA and protein, A, B and C, respectively. UTR, untranslated region of
the mRNA transcript. Reproduced with modifications from[25].
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sclerosis and to prevent CAD. Lifestyle modification
involves educating patients to adhere to a low-fat diet,
exercise and to reduce overweight or maintain an opti-
mal body weight. An effective low-fat diet could lower
LDL-C (LDL cholesterol) by 20% to 30% [28-30]. For
patients who are not able to reach their LDL-C goal
(<129 mg/dI, 3.31 mmol/L) on the lifestyle modification
program, drug therapy is the next step. The current
recommendations for LDL-C goals from the National
Cholesterol Education Program Adult Treatment Panel
III guidelines are <100 mg/dI, 2.586 mmol/L for patients
with very high cardiovascular risk and <129 mg/dI, 3.31
mmol/L for patients with moderate cardiovascular risk
[31]. The preferred and most effective lipid-lowering
agents are the 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase inhibitors, more commonly
known as statins [32]. Statins are the best tolerated
medication in patients of all ethnic groups, both sexes,
and generally, all ages. They also have an excellent
safety profile over the now nearly 20 years of widespread
clinical use, and have the highest level of patient adher-
ence among available lipid-lowering agents with low
incidence of side effects [33]. Because different statins
have variable potency, the therapeutic outcome ranging
from 20% to 60% reduction in LDL-C [32], depends on
t h ep a r t i c u l a rs t a t i nu s e d ,t h ed o s ea n dt h et y p eo f
LDLR mutation. Despite the powerful effect of statins,
they may not be appropriate for those who are best trea-
ted with non-systemic therapy (eg, young adults, women
of childbearing age), who require only a modest reduc-
tion in LDL-C, or those with active liver disease or
increased liver function test values and who predomi-
nantly have hypertriglyceridemia. Increasing the statin
dose to 80 mg (rosuvastatin to 40 mg) is associated with
a threefold increase in liver toxicity or myopathy [34].
Therefore, treatment with non-statin cholesterol lower-
ing agents, for example bile acid resin [35], niacin [36],
fibrate [37] or cholesterol absorption inhibitor [38], is
recommended for these patients.
Bile acid binding resins are non-absorbable anion
exchange resins that bind bile acids in the intestinal
lumen, preventing their absorption from the ilium and
therefore increasing their fecal excretion. The liver
responds by up-regulating cholesterol 7-alpha hydroxy-
lase, which increases the conversion of cholesterol to
bile acids, thereby reducing the cholesterol concentra-
tion in the hepatocyte [39]. Gastrointestinal distur-
bances, and drug and/or fat-soluble vitamin
malabsorption, which were associated with early genera-
tion bile acid resins, have been overcome with new gen-
eration agents [35]. Bile acid resins can lower LDL-C
approximately 10% to 25% which is appropriate for
patients who need only moderate LDL-C lowering [35].
Niacin, or nicotinic acid, is the oldest lipid-lowering
drug dating back to the 1950s [39]. Depending on dose
and formulation, LDL-C reductions of 12% to 20%
maybe anticipated, along with good reductions in trigly-
cerides and 17% to 31% increase in high-density lipopro-
tein cholesterol (HDL-C). The major drawback to niacin
use is its side effects, which include itching, headaches
and hepatotoxicity. It is contraindicated in patients with
active liver disease or unexplained abnormalities in liver
function tests [39].
A cholesterol absorption inhibitor, more commonly
known as Ezetimibe, impairs dietary and biliary choles-
terol absorption at the brush border of the intestine
without affecting the absorption of triglycerides or fat-
soluble vitamins [19]. It has been shown to be well tol-
erated and effective in lowering LDL-C when used as a
monotherapy or when adding to statin therapy. Ezeti-
m i b ea tad o s eo f1 0m g / d a yr e d u c e dL D L - Cb y
approximately 17% with no adverse effect of myopathy
or liver toxicity [40,41]. However, recently concerns
have been raised in respect to an independent athero-
genic property of this drug, which appears to counteract
its cholesterol-reducing action [42].
For patients who do not respond to a maximum dose
of a statin and those who develop side effects with higher
doses, a combination therapy of statin with one of the
above agent, rather than an increase in the statin to high
doses, may be more effective in achieving LDL-C goals
and improving CAD outcomes while remaining at an
acceptable safety profile [43]. Adding a bile acid resin or
niacin to the statin can reduce LDL-C by approximately
50%, depending on the choice of statin and dosage pre-
scribed [44,45]. Co-administering 10 mg of ezetimibe
with any dose of statin reduced LDL-C levels by an addi-
tional 25%, compared with the usual 6% attained by dou-
bling the statin dose [46]. However, even after treatment
with a combination therapy, the majority of homozygous
and minority of heterozyogotes FH patients may still
have extremely raised LDL-C serum levels [47] and their
risk of CAD remains unacceptably high.
Surgical interventions involving a portocaval shunt or
an ileal bypass have yielded transient lowering of plasma
LDL in these patients [48]. The preferred treatment at
present is an aggressive programme of plasma apheresis
or LDL apheresis, a physical procedure in which LDL is
selectively removed from the blood by passing plasma
over columns that bind the LDL. A small number of
angiographic regression studies have been conducted and
each weekly or fortnightly treatment has been demon-
strated to lower LDL-C levels by about 55% and to delay
onset and progression of atherosclerosis [49-53].
The most significant but also most aggressive meta-
bolic correction is orthotopic liver transplantation in
homozygous patients [54-56]. However, the morbidity
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are serious limitations.
Several novel therapeutic approaches have also been
developed recently to lower LDL-C, either as monother-
apy or in combination with statins [57] including; squa-
lene synthase inhibitors [58], microsomal triglyceride
transfer protein inhibitors [59,60], siRNA for PCSK9
[61] or for apolipoprotein B-100 [62] silencing, antisense
PCSK9 [63], and antisense apolipoprotein B-100 (more
commonly known as Mipomersen sodium (ISIS
301012)) [64,65].
In August 2010, Genzyme Corp. and Isis Pharmaceuti-
cals Inc. announced the completion of the four phase 3
clinical trials that are required in the initial United States
and European of regulatory filings for mipomersen. Filings
for therapeutic use in homozygous FH are expected in the
first half of 2011 [66]. These double-blinded, placebo-con-
trolled clinical trials have been conducted at several loca-
tions worldwide. They involve heterozygous FH patients
[67], homozygous FH patients [68], and patients with
severe hypercholesterolemia [69]. The latter are defined by
LDL-C levels ≥200 mg/dL and baseline cardiovascular dis-
ease (CVD) or by LDL-C levels ≥300 mg/dL without CVD.
The trials also include patients with high cardiovascular
risk [70] and high cholesterol levels as defined by LDL-C
levels ≥100 mg/dL who were already taking maximally tol-
erated lipid-lowering medications.
At the end of the study, these patients had an average
LDL-C reduction of 36-37% with no serious adverse
effects. The reductions observed in the study were in
addition to those achieved with the patients’ existing
maximally tolerated statin regimens. The trial also met
each of its three secondary endpoints with statistically
significant reductions in apo-B, non-HDL-cholesterol
and total cholesterol. All trials also demonstrated man-
ageable safety and tolerability profile of mipomersen.
Although each of these novel therapies effectively low-
ers LDL-C, challenges remain for clinical development
in the assessment of long-term safety.
Liver directed gene therapy for FH
Patients who have undergone liver transplantation and
have experienced substantial reductions in LDL-C levels
provide indirect evidence that gene therapy targeted
towards the liver could be effective for this disease.
While LDLR is expressed by the majority of body cells,
hepatic reconstitution of LDLR expression alone may be
sufficient for metabolic correction [71,72]. The liver is
an attractive organ for FH gene delivery because of its
large mass, its ability to synthesise large amounts of pro-
teins, its central position in metabolism and its good
accessibility through the portal vein [72,73].
The homozygous form of FH would be an excellent can-
didate for gene therapy since the plasma lipid profile, total
cholesterol, LDL-C, HDL-C and LDL/HDL ratio, can be
measured providing a convenient clinical endpoint to eval-
uate the response to therapy [71,72]. In addition, a sensitive
non-invasive method using a scintillation camera is avail-
able to determine the location, magnitude, and duration of
LDLR transgene expression which could provide functional
transgene expression in gene therapy trials of FH [74].
Moreover, animal models are available, which include the
Watanabe heritable hyperlipidemic (WHHL) rabbit [75],
and rhesus monkeys [76], the ApoE-knockout (ApoE-/-)
mouse [35], and the LDLR-knockout (LDLR-/-) mouse
models [77]. The WHHL rabbit demonstrates hypercholes-
terolaemia due to natural deletion of 12 nucleotides in the
LDL-binding domain of the LDLRcDNA [78]. This causes
a delay in the post-translational processing of the 120 kDa
LDLR-precursor to the 160 kDa mature form, leading to
premature degradation of the mature form in the cyto-
plasm and consequently hypercholesterolaemia (700-1200
mg/dl at 12 months of age) [79]. The WHHL rabbit, there-
fore, demonstrates metabolic and clinical abnormalities
similar to those in patients with FH and may be a more
authentic FH model than the LDLR-/- or ApoE-/- mouse
models [80] where the raised plasma cholesterol levels (225
± 27 mg/dl) are lower unless the animals are subjected to a
high cholesterol diet. There are also some intrinsic differ-
ences in the lipoprotein metabolism of mice compared to
humans and rabbits. For instance, the main lipoprotein in
plasma of FH patients and the WHHL rabbit is LDL, but
in ApoE-/- mice [81] it is the VLDL fraction with apoB-48,
and HDL and LDL in LDLR-/- mice [77]. The activity
levels of the plasma cholesterol-ester transfer protein
(CETP), which facilitates the transport of cholesteryl esters
and triglycerides between the lipoproteins, and hence plays
a role in LDL particle remodelling, are high in WHHL rab-
bits, although murine models lack this activity [80,82].
Consequently, HDL levels in the plasma are low in WHHL
rabbits but high in mice and rats. In contrast, the ApoB-
editing enzyme is not expressed in the liver of rabbits [80],
but murine models do have ApoB-editing activity in the
liver [81]. Therefore, apoB-48-containing VLDL is secreted
from the liver in mice [80,81]. Selective breeding of
WHHL rabbits resulted in coronary atherosclerosis-prone
WHHL rabbits manifesting with features of coronary and
aortic atherosclerosis and myocardial infarction, in contrast
murine models are usually resistant to the development of
myocardial infarction and features of coronary and aortic
atherosclerosis [80]. For the above-described differences,
the WHHL rabbit is thought to be a more authentic FH
model similar to human subject (reviewed in [80]).
Methods of gene delivery
Gene transfer can be performed either ex vivo, involving
isolation of autologous cells from the patient, their in
vitro genetic modification and selection followed by
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in vivo, where the vector is delivered directly to the
organ [83]. The advantage of the ex vivo approach is
that the transduction/transfection conditions can be
carefully controlled and optimised and individual clones
with the most desirable characteristics can be isolated to
eliminate unmodified cells or cells with deleterious
mutations before re-implantation. While this approach
is laborious and time consuming, it may also offer sig-
nificantly greater safety and control with respect to vec-
tor mediated mutagenesis and possible germline
transmission of the transferred genes, which is a risk of
in vivo gene delivery. The disadvantages of the ex vivo
approach are failure of cell engraftment and difficulties
in returning the cells to the patient due to disease mani-
festations such as portal vein hypertension [83,84].
The in vivo approach eliminates the need for engraft-
ment after re-implantation and is therefore easier to
perform, more cost effective and may be more applic-
able for use in countries with limited laboratory
resources. The gene transfer vector is injected into the
bloodstream (systemic delivery) aiming at somatic cell
delivery only or by use of specific cell targeting, prefer-
entially to the tissues of interest (targeted delivery).
Organ specific delivery of the gene transfer vector
includes intrahepatic injection or selective intravasular
application routes. Disadvantages of in vivo gene trans-
fer are vector dilution, ectopic transgene expression and
non-targeted, random, potentially genotoxic insertion
into the host genome.
Gene transfer systems
In addition to the method chosen for delivery, successful
treatment of FH would ideally require safe and efficient
gene transfer vectors that provide appropriate and sus-
tained levels of transgene expression and long-term sur-
vival of treated cells. The use of a liver specific
promoter would be the most physiological approach to
achieve this. However, because of present problems in
transfection-efficiency, strong heterologous promoters
are commonly used instead for proof of principles stu-
dies on the effectiveness of lipid-lowering. The develop-
ment of more effective vectors to achieve this remains a
formidable challenge to gene therapy. The properties
required of such a vector system and those that should
be avoided are listed in Table 1.
Gene transfer vectors are generally classified under
two categories; they are either non-viral or virus
mediated gene transfer systems.
Non-viral gene transfer systems
Gene therapy vectors based on modified viruses are
unquestionably the most effective gene delivery systems
in use today. Their efficacy at gene transfer is however
tempered by their potential toxicity [85,86]. An ideal
vector for human gene therapy should deliver sustain-
able therapeutic levels of gene expression without com-
promising the viability of the host (at either the cellular
or somatic level) in any way. Non-viral vectors are
attractive alternatives to viral gene delivery systems
because of their low toxicity, relatively easy production
and great versatility [87].
Most of the non-viral vectors that have been described
for gene therapy are based on complimentary DNA
(cDNA) gene sequences driven by highly active promo-
ters. The DNA in these vectors is typically formulated
with cationic agents to form complexes, which protect
the DNA and facilitate cell entry [87,88]. DNA can,
however, be driven into cells by physical means and the
liver is particularly amenable to gene delivery via hydro-
dynamic delivery. Mahato et al reported that a standard
tail vein injection of naked DNA into mice resulted in
almost no gene expression in major organs due to its
rapid in vivo degradation by nucleases and clearance by
the monocular phagocyte system [89]. However, a very
rapid injection of a large volume of naked plasmid DNA
solution (e.g. 5-10 μg of DNA in 2.5 ml saline, which is
almost equivalent to the blood volume of the animal,
within 5-7 seconds) via the same route induced efficient
gene transfer particularly in the liver [90]. This proce-
dure was applied in one of the first non-viral approaches
to reverse hypercholesterolaemia in an FH model. In
these experiments a DNA construct was produced
which encoded a fusion-protein consisting of a soluble
form of the LDLR combined with transferrin. The strat-
egy of this approach was based on the ability of the
fusion protein to be capable of binding both plasma
LDL and the cellular transferrin receptor. When applied
in vivo following hydrodynamic injection [91], this pro-
tein was shown to bind circulating plasma LDL and to
mediate its clearance through the transferrin receptor
on hepatocytes. Although the system proved functional,
a statistically significant change in the lipoprotein profile
of an animal model was not demonstrated and the pos-
sible immunogenicity of the fusion protein potentially
precludes its utility.
In contrast to using a cDNA expression cassette, the
use of a complete genomic DNA locus to deliver an
intact transgene with its native promoter, exons, all
intervening introns, and regulatory regions with flanking
non-coding genomic DNA sequences may allow regu-
lated complementation of LDLR deficiency in the liver
of hypercholesterolaemic an i m a l s .I n2 0 0 3 ,ab a c t e r i a l
artificial chromosome containing the entire LDLR geno-
mic locus and based on the Epstein Barr Virus (EBV)-
retention system was delivered to LDLR deficient Chi-
nese hamster ovary cell line (CHOldlA7) [92], and
achieved correction of the cells’ deficiency phenotype
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expression at significant levels in the CHOldlA7 cells
and in human fibroblasts derived from FH patients for 3
months and to retain the classical expression regulation
by sterol levels in these cells. These initial studies paved
the way for the development a more sophisticated vector
which utilised a Scaffold Matrix Attachment Region (S/
MAR) rather than a potentially toxic viral component to
provide episomal maintenance [94]. In this study the
LDLR genomic locus was incorporated into an HSV-1
amplicon vector, which was shown to remain episomal
for 11 weeks and provided the complete restoration of
human low density lipoprotein receptor LDLR function
in CHOldlA7 cells to physiological levels. The vector
comprised the LDLR gene driven by 10 kb of the
human LDLR genomic promoter region including the
elements, which are essential for physiologically regu-
lated expression. By utilizing the genomic promoter
region it was demonstrated that long-term, physiologi-
cally regulated gene expression and complementation of
receptor deficiency could be obtained in culture for at
least 240 cell-generations. Importantly, this vector was
shown to be sensitive to the presence of sterols or sta-
tins, which modify the activity of the LDLR promoter.
These in vitro studies finally lead to the successful
administration of genomic LDLR vectors in vivo via
hydrodynamic delivery [95,96]. When administered
hydrodynamically in mice it was demonstrated that effi-
cient liver-specific delivery and statin-sensitive expres-
sion could be obtained for up to 9 months following
delivery [96].
While the majority of studies were focused on treating
FH by inhibition of hypercholesterolaemia through up-
regulation of LDLR or other surrogate lipoprotein recep-
tors (as will be discussed later), an alternative approach
was to down-regulate apoB-100 LDLR-ligand or PCSK9
[63] expression. Down-regulation of apoB-100 by con-
tinues intravenous/subcutaneous administration of
Mipomersen antisense apolipoprotein B-100 oligonucleo-
tide had been attempted in several clinical trials achieving
average LDL-C reduction of 36-37%. Although, the most
common adverse event of these trials was erythema at
the injection site due to the protocol [64,65,97-102], chal-
lenges remain for clinical development in the assessment
of long-term safety.
Recombinant virus-based gene transfer systems
Recombinant viral vectors are usually more effective
than non-viral vectors in mediating cell entry and
nuclear transfer of therapeutic genes in the target cells.
In addition natural tropism of viral envelopes and sero-
types can be employed to achieve targeting selectivity
for particular host cells. Most of these vectors have
mechanisms to avoid intracellular degradation and over-
come cellular and immunological barriers to the delivery
of the genetic cargo. Generation of a virus vector
requires the transformation of a potentially harmful
virus from a pathogen into a gene transfer agent whilst
retaining the viral infectivity. Hence, the first step is to
make the vector replication defective (incapable of pro-
ducing infectious viral particles in the host’st a r g e t
cells). Replication deficient viral vectors are developed
by deletion of crucial genes in the virus genome, which
are then generally replaced by the therapeutic gene. The
elements removed in this way have to be provided in
trans in order to support vector production. This can be
achieved by use of a helper virus or a packaging (pro-
duction) cell line transfected with the plasmids expres-
sing the genes coding for the required structural virus
components and replication proteins. Helper virus must
be purified away from the final vector batches intended
for safe gene delivery.
Recombinant viral vectors presently used are generally
classified under two categories; integrating or non-inte-
grating viral vectors [103]. This distinction is an impor-
tant determinant of the suitability of each vector for a
particular application. Present integrating vectors rely
on random insertion of the transgenic DNA into the
cell’s genome, leading to stable integration and subse-
quent passage to the cell’sp r o g e n y .T h i sg e n ei n s e r t i o n
via non-homologous end joining of vector DNA to that
of the host using a virus integrase can be most
Table 1 The properties required for development of an ideal vector system and those that need to be avoided.
Properties needed Properties to be avoided
Stable high titre vectors Vector degradation
Simple and reproducible production Replication competent virus
Unlimited packaging capacity Expression of undesirable viral proteins
Efficient gene transfer to the target cells Germline gene transmission
Controlled genomic integration Insertional mutagenesis
Regulated normal levels of expression Inappropriate toxic expression
Ability to repeat delivery if needed Severe immune response against vector system
Long-term expression Immune response against transgene products
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vectors. Adeno-associated viral vector integration is less
frequent than that of the unmodified parent virus,
which targets preferentially into chromosome 19 and
does not show the locus specificity of wild-type virus. It
is important to note that integration does not guarantee
stable transgene expression due to host mediated gra-
dual silencing of gene expression over time [104],
immuno-elimination or physiological cell death of gene
modified cells.
Non-integrative vectors such as adenovirus and herpes
simplex viral vectors allow transient episomal expression
of a foreign gene in the target cells. Because of their epi-
somal maintenance, the transferred genes are usually lost
over time by dilution at cell division in actively dividing
cells or by degradation in non-dividing cells [105]. A
non-integrative vector could ideally be delivered repeat-
edly if required, as long as no immunological reactions
develop against the vector or transgenic protein. Unlike
adenovirus and herpes simplex viruses, EBV is stably
maintained without integration in permissive proliferat-
ing cells due to the EBV nuclear antigen 1 protein-
mediated replication and segregation, providing long-
term transgene expression [106]. It is however unlikely to
be used in a clinical setting due to its association with
Burkitt’s lymphoma. The properties of the most com-
monly used viral vectors are summarised in Table 2.
Retrovirus based vectors
Retroviruses (RVs) are a large family of enveloped RNA
viruses, which are generally classified into three subfa-
milies; oncoretroviruses, lentiviruses and spumaviruses
(foamy viruses). The RV particle is composed of two
copies of an RNA genome held together primarily by a
sequence called the dimer linkage, which is termed the
leader region and found in some cases in gag coding
region. The genome is surrounded by a spherical or
cylindrical shaped core and an enveloped glycoprotein,
(Figure 2-A). Upon infection, RVs are able to convert
their RNA genome in the host cytoplasm to DNA
through reverse transcription (RT) [107].
The genome size of simple RVs is approximately 8-12
kb and comprises three main genes; the group specific
antigen encoding gene (gag), the polymerase encoding
gene (pol), and the envelope glycoprotein encoding gene
(env), which are flanked by elements called long term-
inal repeats (LTRs ) ,F i g u r e2 - B .T h egag gene encodes
the viral structural core proteins, which form the matrix,
capsid and nucleocapsid, generated by protease cleavage
of the Gag precursor protein. The pol gene expresses a
complex of enzymes that are involved in particle
maturation (protease), DNA metabolism (reverse tran-
scriptase) and proviral integration (integrase). These
enzymes are usually derived from the Gag/Pol precursor.
The env gene encodes the surface glycoprotein and the
transmembrane protein of the virion, which form a
complex that interacts specifically with cellular receptor
proteins. The genes in the viral DNA are bracketed by
the LTRs, which define the beginning and the end of
the viral genome. The LTRs are identical sequences that
can be divided into three elements. U3 is derived from a
sequence unique to the 3’ end of the RNA, R is derived
from a sequence repeated at both ends of the RNA, and
U5 is derived from a sequence unique to the 5’ end of
the RNA. The genesis of the LTR elements lies in the
process of reverse transcription. U3 contains most of
the transcriptional control elements of the provirus
(viral genome, which has integrated into the chromoso-
mal DNA of a cell), which include the promoter and
multiple enhancer sequences responsive to cellular and
in some cases viral transcriptional activator proteins.
The site of transcription initiation is at the boundary
between U3 and R of the 5’ LTR and the site of poly(A)
addition is at the boundary between R and U5 at the 3’
LTR, as shown in Figure 2-C. The other boundaries of
U3 and U5 are determined by the primer binding site
(PBS) and the polypurine tract (PTT), which are impor-
tant for reverse transcription. Just downstream of the 3’
end of the 5’ LTR, is a short packaging sequence (Psi,Ψ),
which extends into gag and is responsible for encapsida-
tion of the two viral RNA genomes into the capsid. The
att sequences at the ends of the 5’ and 3’ LTRsa r e
necessary for proviral integration [107].
The life cycle of a RV starts with high affinity binding
of the viral envelope glycoprotein to its receptor on the
outer layer of the cell membrane. This interaction leads
to the fusion of the lipid envelope surrounding the
virus, with the target cell membrane. Cell entry of the
viral capsid containing the RNA genome allows the
reverse transcriptase enzyme to copy the viral RNA gen-
ome into a double-stranded DNA, which becomes asso-
ciated with viral proteins to form what is called a pre-
integration complex (PIC). The PIC translocates to the
nucleus where the viral enzyme integrase, which is part
of PIC, mediates integration of the provirus DNA
sequence into the chromosomal DNA of the host cell.
The inserted sequence (provirus) is flanked by complete
copies of LTR sequences. The 5’ LTR drives transcrip-
tion of the RV genome, which gives rise to RNA that
codes for the viral proteins Gag, Pol and Env as well as
for the viral RNA genome, Figure 2-C. Gag and Gag/Pol
proteins assemble as viral core particles at the plasma
membrane which package the viral RNA genomes and
bud from the cell membrane enveloped with plasma
membrane lipid from the host, in which virus derived
Env glycoproteins are embedded [107].
The first generation replication defective retroviral
vectors were developed using Molony Murine
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defective vector particles were produced by a decon-
struction strategy, which aims to dissect/segregate the
viral genome into two transcriptional units (plasmid
constructs). They are the vector genome and the packa-
ging constructs, Figure 3. The vector genome retains all
the necessary cis elements of the vectors and is gener-
ated by replacing viral protein encoding sequences later
to be provided in trans with the transgene of interest.
Both the Ψ signal that is essential for packaging of the
vector genome into the capsid and the viral LTRs, which
are necessary for proviral integration, remain in the vec-
tor genome construct. Expression of the transgenic pro-
tein is driven by the promoter in the U3 region of the 5’
LTR. The packaging construct provides all of the viral
proteins in trans to the vector genome construct (Gag,
Pol and Env). The packaging signal is deleted from the
packaging construct to prevent its incorporation into
viral particles. When both the vector genome and
packaging constructs are present in a producer cell, ret-
roviral vector particles, which are capable of delivering
the vector genome with its inserted gene into new target
cells, are released [108]. The process of gene transfer by
such a vector is referred to as transduction. When these
two constructs are present in cells in an integrated
form, the cell becomes a stable virus producer.
Alternatively, virus can also be produced for a short per-
iod of time after transient co-transfection of the viral
genome alongside with packaging plasmids.
The basic arrangement described above is functional
but unsatisfactory for several reasons. Firstly, the
sequence overlap that remains between the vector and
packaging constructs could result in recombination to
form infectious replication competent retrovirus (RCR).
The overlap exists principally because extensive
sequences of the gag gene are retained in the vector
construct to enhance the efficiency of packaging,
although Gag protein production is prevented by muta-
tion. In addition, overlapping sequences also exist
because the LTRs are retained in the packaging con-
struct to provide both promoter and poly-adenylation
sequences. Secondly, the early MoMLV based vectors
were established in murine NIH 3T3 packaging cell
lines, therefore, the possibility for RCR generation
through recombination between vector constructs and
defective endogenous MoMLV-like sequences present in
the target cells cannot be excluded [109]. Thirdly, vector
particles produced in murine cells can be sensitive to
host compliment mediated inactivation after in vivo
gene delivery [110,111].
In order to minimise the risk of RCR production, an
improved vector system was designed by segregating the
Table 2 General properties of the most commonly used viral vectors.
Properties Adenoviruses AAV Retroviruses Lentiviruses
Wild type viruses 36 kb ds linear DNA 4.7 kb ssDNA 9.2 kb Diploid +ssRNA 8-10 kb Diploid +ssRNA
Pre-existing host
antibodies
Yes Yes Unlikely Unlikely but (may be in HIV
+ve individuals)
Packaging
capacity
8-30 kb 4 kb <8 kb 8 kb expected
Viral titre
(particles/ml)
>10
13 >10
12 >10
9 10
9
Stability Good Good Good Not tested
Integration No <10% integrated Yes Yes
Cellular
localisation
Nuclear Nuclear Nuclear Nuclear
Cell range Non-replicating and replicating Non-replicating and
replicating
Replicating only Non-replicating and
replicating
Levels of
expression
Very high Moderate Moderate Moderate
Duration of
expression
Transient Long Long, but subject to shutdown Long
Immune response Extensive Not known Few neutralis-ing antibodies Not known
Safety issues Inflammatory and toxicity Rearrangement and
inflammatory
Insertional mutagenesis Insertional mutagenesis
Main advantages Extremely efficient transduction
of most tissues
Non-inflammatory
Non-pathogenic
Long-term gene transfer in dividing
cells
Long-term gene transfer in
dividing cells
Main
disadvantages
Capsid mediates a potent
inflammatory response
Small packaging
capacity
Transduces only dividing cells and
potential for oncogenesis
Potential for oncogenesis
kb, kilo base; ssDNA, single stranded DNA; dsDNA, double stranded DNA.
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Page 9 of 25Figure 2 Retrovirus virion, viral genome and RNA transcript. A.) Schematic diagram of virion structure. B.) The genome organisation of an
oncoretrovirus provirus DNA; locations of all genes and the LTR are indicated. C.) Viral RNA transcripts. The full-length transcript serves as the
RNA genome and as a messenger RNA for Gag and Gag/Pol polyproteins. The Env is translated from the spliced transcript.
Figure 3 The genomic organisation of MoMLV and the basic retroviral vector design.
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struct, onto discrete expression units, Figure 4. The risk
of recombination was also further reduced by the use of
heterologous envelope proteins that are derived from
alternative viruses with no homology to parental virus
sequences but are still able to be incorporated into the
viral particle (a process referred as pseudotyping). Pseu-
dotyping may also alter the tropism of the viral vector
and can be used as a powerful tool for cell targeting dif-
ferent host tissues. Pseudotyping of MoMLV and other
RVs with the murine ecotropic (recognising only recep-
tors present on mouse cells), amphotropic (interacting
with receptors on both mouse and human cells) or the
vesicular stomatitis virus glycoprotein (VSV-G) envel-
opes (with broad host range including mammalian and
even insect cells) has been achieved and proven useful
[112,113]. In this improved virus production system,
part of the gag sequence present on the first generation
MoMLV vector is removed from the vector genome
without significant loss of packaging efficiency (it was
subsequently found that part of the gag region is essen-
tial for efficient vector packaging) [114], Figure 4.
The problem of overlapping sequences between the
vector and the packaging construct has been solved by
using heterologous promoters and polyadenylation sig-
nals to drive structural gene expression from the packa-
ging constructs. Strong heterologous promoters like
cytomegalovirus (CMV) can provide high virus titre pro-
duction circumventing the limited titre offered by he
MoMLV LTRs that give low-level gene expression in
producer cell lines not of murine origin. In the vector
genome construct itself, heterologous promoters have
been used to replace the 5’ U3 promoter. In addition,
the 3’ U3 sequences can be significantly deleted as long
as the sequences necessary for recognition by the inte-
grase protein are retained. This is the basis of self inacti-
vating (SIN) vectors where deletion of the viral
promoter and enhancer regions in the 3’ U3 are dupli-
cated during reverse transcription in the 5’ LTR to pre-
vent LTR-driven transcription in infected host cells
which could result in the expression of downstream
inserted proto-oncogenes [115]. Transgene expression in
these vectors is therefore typically and exclusively driven
by an internal heterologous promoter, which allows the
use of regulated and/or tissue specific expression.
Finally, a non-murine producer cell line was used for
vector production to prevent the possible generation of
RCR through recombination with endogenous MoMLV-
like sequences [110].
In the latest generation of RV based-vectors, improve-
ments have also been made in the vector titre (number
of colony-forming units per ml) by the development of
transient plasmid co-transfection systems, which are
capable of producing very high vector titres for a short
period of time in the highly transfectable HEK 293
(human embryonic kidney epithelial cells) cell line [110].
Also some human cells used to generate packaging cell
lines can produce a complement-resistant retroviral vec-
tor [111]. Transfection of HEK 293T cells using SV40
large T antigen to improve vector load and hence vector
titre are used also to circumvent the cytotoxicity of the
highly desirable VSV-G envelope that provides broad
host range infection.
Recombinant MoMLV-based vectors produced by the
strategy described above are efficient gene transfer vehi-
cles, reaching transfer levels in vitro of close to 100%.
They can be produced at a high titre (10
9 infectious
units (lU)/ml) and have the capacity to infect a wide
variety of dividing cells including hepatocytes. The RV
vector genome can also provide transfer of RNA of
approximately 7.5 kb in length.
The critical limitation to the use of RVs is their inabil-
ity to infect non-dividing cells and as the liver is an only
slowly proliferating tissue these vectors are not ideal for
Figure 4 Schematic representation of the improved retrovirus three plasmid co-transfection system. Viral genome is segregated into
three expression plasmids; the vector genome, the Gag/Pol expressing plasmid, and the envelope expressing plasmid. For generation of viral
particles, these plasmids are co-transfected into the HEK 293 producer cells, and virus is released into the supernatant.
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in vivo transduction of the liver, cells have to be either
in a naturally dividing state or to be induced to divide.
Alternatively, the vectors can be used for ex vivo
treatment.
Hypercholesterolaemia has been ameliorated by RV-
based vectors using ex vivo gene delivery in numerous
experimental studies. The original procedure used for
liver-directed gene therapy of FH was based on the ex
vivo approach, which involved re-infusion of autologous
hepatocytes that had been removed from a WHHL rab-
b i ta n ds u b j e c t e dt oin vitro genetic correction with RV
vectors based on MoMLV. Animals transplanted with
LDLR transduced celIs demonstrated a 30-50% reduc-
tion in total serum cholesterol levels persistent for the
duration of the experiment (122 days). Recombinant
derived LDLR mRNA was detected in liver cells for 6
months. There was no apparent immunological response
to the recombinant derived rabbit LDLR [116]. This
study illustrated the potential of the ex vivo approach to
ameliorate hyperlipidaemia associated with FH using a
RV-based vector.
In preparation for human trials with RV-based vectors,
the efficacy, safety and feasibility of ex vivo gene therapy
for FH was further documented in non-human primates
[117,118]. Three baboons were subjected to a partial
hepatectomy and their hepatocytes were isolated, cul-
tured, and transduced with a RV containing the human
low-density lipoprotein (hLDLRcDNA) sequence. Infu-
sion of the genetically modified hepatocytes was per-
formed through a catheter that had been placed into the
inferior mesenteric vein at the time of liver resection.
The baboons tolerated the procedures and were moni-
tored for up to eight months [117]. The safety and effi-
cacy of the ex vivo approach for delivery of gene
transduced hepatocytes via the mesenteric circulation
was further documented in a canine model [118].
The above studies demonstrated the feasibility and
safety of the ex vivo approach, which was then carried
out on a human patient in the first clinical trial for FH
published in 1994. In this trial a 29 year-old woman
with a homozygous receptor defective FH was subjected
to ex vivo gene therapy using an amphotropic RV-based
vector expressing human LDLRcDNA under control of
the CMV enhanced chicken b-actin promoter. The
patient tolerated the procedure and in situ hybridisation
of liver tissue four months after therapy revealed evi-
dence for engraftment of transgene expressing cells. The
patient’s LDL/HDL ratio declined from 10-13 before
vector delivery to 5-8 after vector delivery, an improve-
ment that remained stable for the duration of the
reported observation (18 months). However, kinetic stu-
dies of LDL metabolism including LDL binding, uptake
and degradation were not presented [119]. This trial was
severely criticised with respect to both the suitability of
the patient for this therapeutic intervention and for the
aggressiveness of the protocol, which involved a 25%
hepatectomy [120].
Grossman et al then reported four additional homozy-
gous FH patients subjected to a surgical resection of the
left lateral segment of the liver and re-infusion of the
genetically modified hepatocytes [121]. The patients tol-
erated the infusions of autologous hepatocytes well
without complications. Liver biopsies performed four
months after treatment revealed LDLR transgene
expression in a limited number of hepatocytes by in situ
hybridisation in all four subjects. One of four patients
had a significant and prolonged reduction of about 20%
in his LDL-C levels. Kinetic studies of the LDL metabo-
lism demonstrated that LDL catabolism was increased
in the same patient, which was consistent with increased
LDLR expression [121]. The reason for the only margin-
ally successful lowering of cholesterol levels and the
variable metabolic responses observed in the five sub-
jects studied are presumably due to low gene transfer
efficiency or low expression levels [121]. The variable
metabolic response observed following low-level genetic
reconstitution in the five patients precluded a broader
application of ex vivo liver-directed gene therapy with
RV based vectors, pending improvement of vector effi-
ciency. The following sections review the preclinical
work towards this goal with alternative vector system.
Adenovirus based vectors
Adenoviruses (Ads) are icosahedral particles consisting
of linear, double stranded DNA with a non-enveloped
virion, (Figure 5-A). There are at least 50 different
human adenovirus serotypes with an approximate gen-
ome size of 36 kb. The Ad genome (Figure 5-B) is inti-
mately associated with viral proteins (core) and is
packaged in the viral capsid, which consists primarily of
three proteins; hexon, penton base and fibre-knob. After
infection, the virus genome does not integrate into the
host chromosomal DNA, instead it is replicated as an
episomal (extra-chromosomal) element in the host
nucleus [122].
Because of the ability of adenoviral vectors to infect a
broad range of mammalian cell types regardless of their
replication status, they have been widely used for a variety
of gene transfer applications in vitro [123], in vivo [124]
and in clinical trials [125]. Most adenoviral vectors cur-
rently used are derived from serotypes 2 or 5, which are
endemic and cause upper respiratory tract infection in
humans. Most human individuals have become immune-
sensitised by natural infection during childhood [83].
Vectors derived from serotypes 2 and 5 enter the cells
after attachment to the cellular receptor CAR (coxsack-
ievirus and adenovirus receptor), through the knob of
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thrin-mediated endocytosis after binding of the penton
base to integrins [127]. It is noteworthy that differences
in the tropism of various Ad serotypes indicate that
besides CAR, other cellular receptors also contribute,
suggesting that the host range of Ad vectors can be
altered by use of alternative serotypes.
The first generation of replication deficient Ad vectors
was constructed by replacing one or two viral early (E1
and E2) genes, which are essential for viral replication,
with the transcriptional cassette of interest containing
an enhancer-promoter element and the desired gene.
Vectors in such a configuration have a packaging capa-
city of 6.5-8.3 kb. The recombinant vectors are repli-
cated in cells that express the products of the E1 and/or
E2 genes. Purified high titre stocks of 10
11-10
12 Ad par-
ticles per ml, can be generated and allow high efficiency
Ad mediated gene transfer with strong tropism for the
liver. Cells that were transduced with these vectors
express adenoviral genes at low levels, in addition to the
transgenic protein [128].
The utility of replication defective first-generation
recombinant Ad to mediate hLDLR gene transfer in
hepatocytes derived from FH patients was first examined
and documented in 1993 [123], using the b-actin pro-
moter. The level of recombinant-derived LDLR protein
in transduced FH hepatocytes exceeded the endogenous
levels by at least 20-folds.
Reversal of hypercholesterolaemia was then demon-
strated in LDLR-/- mice fed with a high cholesterol diet
after intravenous injection of a replication-defective Ad
encoding the hLDLR driven by CMV promoter. This in
vivo approach resulted in reduction of the elevated inter-
mediate density lipoprotein (IDL)/LDL ratio to normal
levels, four days after vector delivery [129]. Similarly,
injection of a replication-defective Ad encoding the
hLDLR driven by an optimised CMV promoter into the
portal vein of WHHL rabbits, resulted in over-expression
of hLDLR in the majority of hepatocytes that exceeded
the levels in normal human liver by at least 10 fold.
Transgene expression was stable for 7-10 days but dimin-
ished to undetectable levels within three weeks [130].
Similar studies were also conducted on WHHL rabbits
with Ad vectors containing rabbit LDLRcDNA [131] or
human LDLRcDNA [132]. These studies also resulted in
strong but transient transgenee x p r e s s i o n .H o w e v e r ,t h e
high level of LDLR expression and substantial reduction
of total and LDL cholesterol achieved by adenovirus
LDLR gene transfer in these animal models led to a mas-
sive intracellular lipid (cholesterol and cholesterol ester)
deposition in transduced cells [130,133]. This accumula-
tion resulted from non-physiological over-expression of
Figure 5 Features of adenovirus particle. A.) Structural features of Ad. B.) Genomic organisation of wild type Ad. Reproduced with
modifications from original diagram provided kindly by Dr Simon Waddington.
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intracellular accumulation of the lipid that could not be
compensated by the hepatic cell metabolism [133,134].
The transient expression was not solely due to the
episomal nature of Ad infection but also a result of host
immune responses against adenoviral proteins
[124,135,136]. Co-administration of an Ad vector encod-
ing hLDLR driven by a CMV promoter, with a blocking
antibody directed against CD154 (CD40 ligand) to sup-
press immune responses against the vector and foreign
transgene product in LDLR -/- mice, resulted in long-
term expression of LDLR and maintained cholesterol
levels within and below the normal range for at least 92
days post vector delivery. The loss of hLDLR expression
in non anti-CD154-treated mice also demonstrated the
importance of the host immune response against vector
and transgene products [137].
In direct response to these immunological reactions and
vector cytotoxicity, helper dependent adenovirus (HD-Ad)
vectors were developed, in which additional viral coding
sequences were deleted [138]. This also increases the
insert capacity of the vector to approximately 30 kb.
Nomura and colleagues [139] compared the efficiency of
monkey LDLR gene therapy with that of monkey very low
density lipoprotein receptor (VLDLR) gene therapy, using
HD-Ad. High cholesterol diet fed LDLR-/- mice were
injected with a single intravenous application of high (1.5
×1 0
13 vector particles (vp)/kg) and low (5 × 10
12 vp/kg)
doses of HD-Ad. Throughout the 24-week experiment,
plasma cholesterol of LDLR-treated mice was lower than
that of VLDLR-treated mice. Anti-LDLR antibodies devel-
oped in 2 of 10 mice treated with high-dose HD-Ad-LDLR
but in none (0/14) of the other treatment groups. The
antibody titre in the high-dose experiments was signifi-
cantly above background, but was three orders of magni-
tude lower than that seen following first generation Ad-
LDLR treatment, indicating that the marked pro-inflam-
matory adenoviral protein expression following FG-Ad-
LDLR gene transfer could have acted as an adjuvant that
stimulated antibody production in these mice. Long-term
efficacy of low-dose HD-Ad-LDLR injected into 12-week
old LDLR-/- mice was tested and after 60 weeks, athero-
sclerosis lesions covered approximately 50% of the surface
of aortas of control mice whereas aortas of treated mice
were essentially lesion-free. The lipid lowering effect of
HD-Ad-LDLR lasted at least 108 weeks (>2 years) when
all control mice had died [139].
Despite the reported improvements achieved by HD-
Ad, the cytotoxic effect resulting from immune response
to high titre (3.8 × 10
13 lU/mI) administration of a 2
nd
generation adenoviral vector, which led to the unfortu-
nate death of a patient in a non-FH clinical trial [125]
stopped any further in vivo adenoviral vector delivery
trials, pending improvement in vector design. In an
attempt to address this issue, Jacobs and colleagues
investigated the use of a relatively low dose (5 × 10
10
particles) of second generation E1E3E4-deleted adeno-
viral vectors for transfer of the LDLR or VLDLR, under
control of the hepatocyte-specific human a1-antitrypsin
promoter and 4 copies of the human apo E enhancer,
into C57BL/6 LDLR-/- mice [140]. Evaluation was per-
formed for 30 weeks after vector delivery in male and
female mice fed either standard chow or an atherogenic
diet. Compared to control mice, AdLDLR and
AdVLDLR persistently decreased plasma non-HDL cho-
lesterol in both sexes and on both diets and potently
inhibit development of atherosclerosis in the ascending
aorta. The non-physiologically regulated over-expression
of LDLR or VLDLR, transferred by E1E3E4-deleted ade-
noviral vectors, significantly reduces tissue cholesterol
levels in myocardium, quadriceps muscle, and kidney
and does not lead to pathological intracellular accumu-
lation of cholesterol and cholesterol esters in hepato-
cytes. The effectiveness of the vectors and expression
cassette used in this study is stressed by the fact that,
using vector doses that are 2-7.5-fold lower compared
to those in other studies [139,141], equivalent results
were obtained in terms of lipid lowering and reduction
of atherosclerosis [140]. However, immune response to
the vector system to evaluate potential development of
neutralizing antibody or immune rejection to the trans-
gene and/or vector has not been shown.
Adenoviral based vectors still remain the most effi-
cient class of vector in terms of delivering to and
expressing their genetic cargo in the cells of most tis-
sues. However, because of their transient expression
characteristics, while they remain useful for proof of
principle for gene therapy they are not the vector of
choice for the treatment of inherited monogenic dis-
eases but will probably find application in the treatment
of cancer in which cellular toxicity and immunogenicity
might even enhance their anti-tumour effects [142].
Adeno-associated virus vectors
Vectors based on adeno-associated virus (AAV), a small
(20-25 nm) non-enveloped DNA virus (Figure 6) that is
non-pathogenic and replication-defective, have a num-
ber of attributes that make them suitable for gene trans-
f e rt ot h el i v e rf o rt h et r e a t m e n to fF H .As i n g l e
administration of recombinant AAV (rAAV) into the
liver results in long-term transgenic protein expression
without toxicity in a variety of animal models [143].
These pre-clinical studies have lead to phase I/II trials
of liver gene transfer for diseases such as haemophilia
[144] for example, using AAV serotype 2, the first iso-
late to be characterised.
There are several current obstacles to AAV gene ther-
apy that need to be addressed. Although AAV is not
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lation is sero-positive for AAV capsid proteins [145] and
wild type (wt) AAV2 is endemic to humans. Thus most
of the patients that participated in clinical trials are
likely to have had pre-existing immunity to the serotype
employed, as a result of prior natural infection. Cyto-
toxic T-cells resulting from wt-AAV infection can elimi-
nate transduced cells and anti-AAV2 antibodies are able
to block or reduce gene transfer with rAAV2 vectors.
These factors may have limited transgenic hFIX protein
expression in a recent hemophilia B gene therapy trial
[144]. Switching the capsid protein to other AAV sero-
types that are less prevalent in humans can overcome
these immunological problems [146]. There are several
AAV serotypes available that may prove useful in the
future for clinical translation.
Currently a high multiplicity of infection is needed to
achieve therapeutic AAV mediated gene transfer. Effi-
cient transduction of target cells is blocked at several
levels during AAV cell infection and movement of the
vector into the nucleus. The host gender appears to be
an important consideration, since in mice exogenous
androgens can increase stable hepatocyte gene transfer
in females to levels observed in male mice [147]. Strate-
gies such as blocking endosomal degradation of AAV
with proteasome inhibitors significantly improve AAV
transduction in mice [148,149]. Switching AAV capsid
proteins to an alternative serotype such as AAV8 can
also enhance uncoating of the vector and release of the
genome [146].
The dsDNA genome of the AAV vector can persist as
an episomal element in transduced cells for long periods
of time in a variety of molecular forms, including circu-
lar monomers, linear monomers and linear concatemers
by head to tail recombination of the ITRs. Integration of
single and concatemeric genomes into the chromosomal
DNA of the host cells occurs at low frequency [103].
Because the transgene is predominantly expressed from
the episomal form, expression usually declines over time
due to dilution in the replicating cells or degradation in
non-dividing cells [105]. A recent study found that
administration of Ad 10-20 weeks after AAV gene
transfer augmented AAV transgene expression two-fold
by increasing the level of pro-viral mRNA [149] and this
strategy may prove useful in clinical practice when
transgenic protein expression levels fall.
Slow conversion of the virus single stranded (ss) to the
double stranded (ds) DNA genome is another issue.
After the AAV virus enters the nucleus, the virus single
stranded DNA genome (ssDNA) is converted to a tran-
scriptionally active double stranded DNA (dsDNA)
[150]. Unless the conversion happens, ssDNA is lost
rapidly after transduction, leading to a drop in trans-
genic protein expression. This rate-limiting conversion
process can be circumvented by modifying the config-
uration of the provirus so that it is packaged as comple-
mentary dimer as opposed to the conventional ss [151].
This self-complementary (sc) AAV vector configuration
has been shown to significantly improve gene transfer to
the liver for human factor IX, achieving levels of stable
transduction that are almost one order of magnitude
higher than those achieved with an equivalent dose of
comparable ssAAV [151,152]. Lowering the required
dose of scAAV vector would be of benefit for safety
considerations and for scaling up to clinical grade vector
production. Modifying the promoter can alter the tissue-
specific expression. Use of the liver-specific promoter,
LP-1 for example in a self-complementary AAV2/3 vec-
tor driving the human factor IX (hFIX) protein, resulted
in transgenic h(FIX) proteine x p r e s s i o nc o n f i n e dt ot h e
liver as detected by RT-PCR analysis [152]. This would
be beneficial for FH gene therapy.
One of the earliest studies on AAV vectors for FH
gene therapy found promising results. Reversal of
hypercholesterolaemia was demonstrated in LDLR-/-
mice fed with a high cholesterol diet after intraportal
vascular injection of 1 × 10
12 AAV-2 vector particles
encoding the murine VLDLR driven by the CMV
enhanced chicken b-actin promoter [153]. Western blot
analysis and immunohistochemistry revealed high levels
of VLDLR expression in approximately 2-5% of cells of
liver harvested at 3 and 6 months after vector delivery
with a low vector DNA copy number of 1 copy/cell.
Serum cholesterol progressively declined after vector
Figure 6 Genomic organisation of the AAV and basic AAV vector design.
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tic lesion area was reduced 33% compared with control
mice injected with saline. Phenotypic correction was
incomplete however, primarily due to immune activation
by the vector products and low efficiency of gene trans-
fer mediated by AAV-2.
Lebherz and colleagues [154] compared the efficiency of
AAV-2, -7 and -8 serotype vectors carrying the human
LDLRcDNA expressed from a liver specific promoter
based on the human thyroxin binding globulin [155]. A
vector dose of 1 × 10
12 genome copies (gc) per mouse was
injected into the portal veins of LDLR-/- mice that were
fed a high-fat diet. Transduction efficiency was increased
to 50 gc/cell and 10 gc/cell after treatment with an AAV-8
or AAV-7 vector respectively, compared with 2 gc/cell
after administration of an AAV-2 vector. Animals receiv-
ing the AAV-LDLR serotype 7 and 8 achieved nearly com-
plete normalization of serum lipids and failed to develop
the severe atherosclerosis that characterized the untreated
animals, with no apparent toxicity observed. Animals trea-
ted with the AAV-2 vector achieved partial lipid correc-
tion and only a modest improvement in atherosclerosis.
Serotype 8 virus achieved stable transduction and expres-
sion of the transgene in up to 85% of the hepatocytes.
These results are encouraging especially since no expres-
sion-terminating immune responses were detected [154].
There were similar findings in the apo-E mouse model of
FH, where intravenous administration of AAV2/7- and
AAV2/8-apoE vectors completely prevented atherosclero-
sis at 1 year [156].
Another approach using AAV vectors has been to try
to counteract the development of atherosclerosis by
gene transfer of interleukin-10 (IL10), an anti-inflamma-
tory cytokine. Injection of AAV IL10 vector into the tail
vein [157] of LDLR-knockout mice or into the tibial
muscle [158] of apo-E deficient mice resulted in signifi-
cantly lower levels of atherosclerosis.
More recently, a single intravenous injection of an
AAV8 vector containing the mouse LDLR gene to a
humanized mouse model of FH, the LDLR-/-Apobec-/-
mouse, was found to significantly reduce plasma choles-
terol and non-HDL cholesterol levels in chow-fed animals
at low doses. Treated mice realized an 87% regression of
atherosclerotic lesions with substantial remodeling, after 3
months compared to baseline mice [159].
In summary, modifying the AAV vector system by alter-
ing the capsid (reviewed in [160]), including dsDNA and
using a liver specific promoter may result in long term,
stable and liver specific AAV mediated transgenic protein
expression which may be suitable for FH gene therapy.
Lentivirus based vectors
Lentiviruses (LVs) are a complex sub-group of RVs respon-
sible for a variety of immunological and neurological
diseases. Their biological and molecular and properties
have been used to classify them as lenti-(sIow) retroviruses.
They can be subdivided into primate and non-primate
viruses. The primate viruses are the human and simian
immunodeficiency viruses (HIV and SIV), and the non-pri-
mate viruses include the feline and bovine immunodefi-
ciency viruses, the caprine arthritis/encephalitis virus, the
visna/maedi/ovine progressive pneumonia virus, and the
equine infectious anaemia virus (EIAV) [107]. As for all
RVs, the LV genome consists of a positive-strand polyade-
nylated RNA of about 10 kb and includes three genes; gag,
pol,a n denv organised in the 5’ to 3’ orientation. Lenti-
viruses have additional unique small ORFs located between
pol and env at the 3’ terminus, which contain genes for reg-
ulatory proteins [107].
Interest in LVs as putative gene transfer systems is
derived from the fact that they have the potential to
integrate efficiently into the genome of dividing and
non-dividing cells providing the possibility for lifetime
correction with a single administration of vector
[161,162]. Unlike the RV pre-integration complex, which
can only reach the target cell nucleus when the nuclear
membrane is disrupted during mitosis, the lentiviral PIC
contains nuclear localisation signals, which mediate
their transport through nuclear membrane pores into
the nucleus during the cell interphase [163-165].
Although integration of linear DNA episome, provirus
precursor, is generally regarded as the end point of gene
transfer, two circular episomal types with intact viral
coding regions are also generated by cellular proteins
from retro- or lenti-viruses and their derived vectors
[166]. The first type circularizes by non-homologous
recombination of end-joining to form a circular episome
with two adjacent LTRs (2-LTR circular episome) [167].
The second type circularizes by homologous recombina-
tion within the LTRs to form a circular episome with a
single LTR (1-LTR circular episome) [168]. It has been
estimated that approximately one-third of linear lenti-
viral DNA become circular episomal forms and can
express proteins and remain metabolically stable and
transcriptionally competent in target cells, although, the
single LTR circular episomal forms are more prevalent
than 2-LTR circles [166].
Using a LV backbone, two types of vector system can
be produced and used for gene transfer, the first are
integrated lentivirus based vectors (ILV) and the second
are integration deficient lentiviral vectors (IDLV). Initial
research on the development of lentivirus-based vectors
has focused mainly on HIV-1 derived integrated LV vec-
tors as prototype. This is facilitated by the abundance of
knowledge that has been accumulated on this virus
since its recognition in 1984 as the causative agent of
acquired immuno-deficiency syndrome. Like other
virally derived vectors, the initial problem to overcome
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replication deficient [161,162]. The LV based vector
design is very similar to that of the three-plasmid co-
transfection RV system based on MoMLV, described
above. In addition, the emergence of a host immune
response against lentiviral vectors has not been shown
in most of the preclinical studies [169-173].
Due to the increased concern of insertional mutagen-
esis (IM) caused by integrating retro- and lentivirus
based vectors (as will be discussed later), IDLVs has
been thought of as a logical alternative to alleviate the
risk of IM. IDLV particles can be generated by the use
of integrase mutations that specifically prevent proviral
integration resulting in the generation of increased levels
of circular vector episomes in transduced cells, but not
to compromise its other functions, Because these lenti-
viral circular episomes lack replication signals, they are
g r a d u a l l yl o s tb yd i l u t i o ni n the transduced actively
dividing cells, but are stable for several months in trans-
duced quiescent cells [174-176]. Compared to integrat-
ing lenti-vectors, IDLVs have a significantly reduced risk
of causing IM, a lesser risk of generating RCRs, a
reduced risk of transgene silencing [177], and also extre-
mely low levels of integration (residual background inte-
gration frequencies of IDLVs in cultured cells through
non-integrase pathways are within the range described
for plasmid transfection (reviewed in [166,178]).
Recent studies using IDLVs have demonstrated effec-
tive gene transfer in the eye [176], brain [174,179], mus-
cle [180], and to a lesser extent in the liver [181], albeit
at lower expression levels than with integrating vectors.
In addition to gene transfer, IDLVs are also proficient
vectors for gene repair and can be converted into stable,
replicating circular episomes. These properties, com-
bined with their highly reduced risk of causing IM, have
led to increased interest on IDLVs for gene transfer and
therapy. Because of the possibility of mobilization by
superinfection with replication competent viruses, it has
been suggested that future IDL-based vectors should
carry att mutations in addition to those in the integrase
to minimize integration in the event of vector mobiliza-
tion (reviewed in [166,178]). Long-term evidence for
lack of genomic integration beyond residual levels war-
rants future investigation. To date, IDLVs have not been
used for LDLR gene transfer and FH gene therapy.
Many labs including ours [182] experienced difficulties
to produce infectious ILVs for transfer and expression of
human LDLR under control of a ubiquitous promoter.
However, based on the utilisation of a previously charac-
terised liver specific promoter (LSP) [183], Kankkonen
and colleagues were able to demonstrate for the first
time the successful construction and production of high
titre (1 × 10
9 IU) third-generation HIV-1 based lentiviral
vectors encoding rabbit LDLR. LSP-driven transgene
expression was detected after in vitro gene transfer into
human hepatoma (HepG2) cells, but not after transfer
into HeLa cells, HEK 293 cells, or WHHL rabbit skin
fibroblasts [183,184]. In vivo injection of 1 × 10
9 infec-
tious virus particles into the portal vein of WHHL rab-
bits resulted in liver-specific expression of the LDLR
and clinical chemistry and histological analyses showed
normal liver function and morphology during the 2-year
follow-up without safety issues. This vector dose
resulted in low transduction efficiency (<0.01%) but
demonstrated on average a147 ± 7% decrease in serum
cholesterol levels during the first 4 weeks, a 44 ± 8%
decrease at 1 year and a 34 ± 10% decrease at the 2-
year time point, compared to the control rabbits
infected with HIV-green fluorescent protein. During this
period, 70% of the rabbits treated with the liver specific
lentiviral LDLR vector demonstrated a positive treat-
ment effect with lowered plasma cholesterol levels (25 ±
8%). However, the detailed pattern of bio-distribution
after HIV-vector mediated gene transfer, to evaluate
potential risks for possible IM and germ-line transmis-
sion, has not been investigated.
Vector safety in gene therapy
The integration of RV and LV into the genome during
gene therapy has caused concern because of the poten-
tial for vector-related deleterious side effects on the
host. This is, in part, due to the fact that vector inser-
tion occurs in a semi-random manner into actively tran-
scribed genes. For RV vectors insertion preference is for
gene promoter regions [185-188] whereas LVs appear to
target the transcription unit of the gene [189,190] and
therefore are believed less likely to cause effects on host
gene expression following integration [191-194]. Geno-
toxicity by RV vectors associated with insertional muta-
genessis (IM) has been studied for several years and the
theoretical calculated estimates of mutagenesis at a hap-
loid locus are supported by in vitro studies using model
systems based on mutagenesis of the hprt locus or
genes that control promotion of growth factor indepen-
dence at frequencies between 10
-5-10
-7 per provirus
insertion [191,192]. Hence, the likelihood of adverse
events caused by RV integration following therapeutic
application was considered remote. Unfortunately and
unexpectedly, however, development of clonal domi-
nance has been observed in two patient trials that is
attributed to RV mediated IM [86,195-199].
In an ex vivo trial carried out in France that used
patients’ own haematopoietic stem cells for transplanta-
tion after retroviral transduction to correct X-linked
severe combined immuno-deficiency (X-SCID), clonally
dominant clones have developed into leukaemias in 4 of
these patients [85,86,196]. This also occurred in one
patient in a British X-SCID trial [198]. In 4 of these
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IM by inserting near the LMO2 gene [196,198]. In addi-
tion, insertions have been found in both BMI1 and
CCND2 proto-oncogenes [196,198]. Although 5 out of
the 20 patients that enrolled in the French and British
trials have developed leukaemia it is difficult to under-
stand clearly the events leading to this disease because
of existing genetic abnormalities in the patients’ cells
that have also been identified. These include chromoso-
mal translocations, gain-of-function mutations activating
NOTCH1, deletion of tumour suppressor gene
CDKN2A, 6q interstitial losses, and SIL-TAL1 rearrange-
ment [196,198].
In a more recent trial for chronic granulomatous dis-
ease (CGD) clonal dominance has also been attributed
to retrovirus mediated IM 5 month after vector delivery
in 2 patients [199]. Vector integrations activated the
zinc finger transcription factor homolog’sM D S 1 / E V I 1 ,
PRDM16 or SETBP1 raising concerns that this could
eventually cause tumourgenesis. The first affected
patient died 2.5 years after vector delivery as a result of
a severe sepsis and the second patient has undergone
allogeneic transplant [199,200].
In response to these findings, ex-vivo and in vitro
models have been developed in order to examine RV
and LV genotoxicity using haematopoietic cells. Ex vivo
gene therapy using stem cells is considered a more con-
trollable way of introducing genetic modification to the
host than by direct systemic vector administration in
vivo [201-205]. These models have confirmed that inser-
tion of RV, and to a lesser extent SIN-RV and LV can
contribute to leukaemic development [85,201-206]. Fac-
tors implicated in this process include the integrated
vector copy number, integration sites, vector configura-
tion and even the transgene carried by the vector
[85,201-206]. Most recently, host cell transcription, in
combination with the mutational potential of the vector,
has been shown to be involved in the emergence of clo-
nal dominance [206,207].
In our laboratory we have developed a model more
suited to gene therapy for FH where vectors may be
delivered directly in vivo. In this model vector applica-
tion in utero is performed via the fetal mouse circulation
that results in gene transfer to most organs, although
the liver is mainly transduced [208]. We found that
using a primate HIV-1 based vector carrying the human
factor IX (hFIX) gene to correct haemophilia in a
knockout mouse model of this disease comprehensive
cure was achieved without adverse effects, however, the
use of a non-primate EIAV vector driving hFIX gene
expression led to a high frequency of liver tumours in
these mice [209]. This model is still under development,
and we have also obtained similar results with the non-
primate feline immuno-defificiency (FIV) vector (Themis
et al. unpublished data). Most importantly in these
tumours, we find insertions within genes assigned as
candidate genes involved in cancer development (within
a 100 kb integration site window - the theoretical dis-
tance by which vector insertion is believed to influence
expression of a gene carrying the integrated vector).
More than 50% of these genes are registered in the
Mouse Retroviral Tagged Cancer Gene Database
(RTCGD) [210]. Furthermore, many genes carrying
insertions have altered gene expression suggestive of IM
by the non-primate LV. Hence, using in utero gene
delivery where genes are in a highly active transcription
state, we are able to sensitively detect adverse effects
caused by vector integration.
The current models for vector associated genotoxicity
all rely on the use of rodent cells as a measure of IM.
As these cells are more predisposed to tumour develop-
ment than human cells, each must be viewed with cau-
tion as reliable predictors for mutagenesis occurring in
the clinic. The finding of vector genotoxicity in the
clinic has, however, revived the use of models of geno-
toxicity to obtain useful information regarding safe vec-
tor design. They may also help to elucidate possible
mechanisms relating to IM. In summary, the importance
of genotoxicity assays to understand the cause and mea-
s u r et h er i s ko fa d v e r s ee f f e c t sb yg e n et h e r a p yo fF H
and indeed the treatment of any disease with these vec-
tors cannot be overstated. With the current genotoxicity
assays in place we are becoming more confident that
gene therapy to FH homozygotes will be possible with
minimal side effects.
Conclusion
Several novel therapies have been developed recently to
lower LDL-C in homozygous and heterozygous FH
patients [57-65,211]. However, their major drawback is
the need for life-long repeated administration in a simi-
lar manner to conventional pharmacological drugs. The
advantage of gene therapeutic intervention over other
therapeutic regimes is the potential for lifetime correc-
tion with a single vector administration. Yet, this goal
still needs to be achieved. Despite the considerable pro-
gress, made in optimising the two most commonly used
gene therapy vector-groups based on retro- and adeno-
viruses, neither vector has been found to be ideal for in
vivo and/or ex vivo gene transfer. Vectors derived from
AAV and LVs are very promising. However, the onco-
genesis risk from semi-random integration into actively
transcribing genes of the host by LVs [189,212,213],
possible germline transmission [214] and some immu-
nological reaction after AAV gene transfer in the human
haemophilia-B trials [144,215] are critical drawbacks
that require further vector development and
improvement.
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the successful use of the VLDLR as an effective surro-
gate lipoprotein receptor gene [139-141,153,216,217] for
the complementation of mutated LDLR function in
homozygote FH patients would also open an alternative
therapeutic avenue, since it would avoid the immune
problem in patients with no natural LDLR. Despite the
fact that most of the pre-clinical and clinical studies
were aimed at treatment of the homozygous form of
FH, a minority of heterozygous FH patients, who are
refractory to existing pharmacological therapy, are also
possible targets. Therefore, once a safe and efficient
transfer vector is developed and shown to be effective in
homozygous FH, its application might be extended to
severe heterozygous FH as well. Clearly there is also an
urgent demand for safe and efficient vectors that would
integrate into the host genome and provide long-term
appropriate gene expression for in vivo and/or ex vivo
gene therapy of FH and many other human diseases.
Future work will generally focus on making gene
transfer vectors safer by improving their immunogenic,
integration, expression and targeting profile. Reducing
the inherent oncogenic danger of integrating vectors by
engineering conditional suicide genes into the vector
backbone to provide a self-destructive mechanism in
case of oncogenesis or by targeting their integration into
specific pre-defined benign genomic sites, i.e. by zinc-
finger nuclease technology, may help achieving this goal
[218]. In combinations with the above strategies, the use
of ex vivo transduction to reduce vector spread can also
improve the safety outcome, particularly, if autologous
or induced pluripotent stem cells are the target. The
application of viral or non-viral, integrating or non-inte-
grating vectors for long term persistence in stem cells
with self renewal and differentiation capacities will also
be important perspectives for gene-based stem cell
therapy.
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